Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 97 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ventilator Associated Pneumonia (VAP) - Pipeline Review, H1 2015', provides an overview of the Ventilator Associated Pneumonia (VAP)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ventilator Associated Pneumonia (VAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ventilator Associated Pneumonia (VAP) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ventilator Associated Pneumonia (VAP) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ventilator Associated Pneumonia (VAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ventilator Associated Pneumonia (VAP) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ventilator Associated Pneumonia (VAP)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Ventilator Associated Pneumonia (VAP) Overview 8
Therapeutics Development 9
Pipeline Products for Ventilator Associated Pneumonia (VAP) - Overview 9
Pipeline Products for Ventilator Associated Pneumonia (VAP) - Comparative Analysis 10
Ventilator Associated Pneumonia (VAP) - Therapeutics under Development by Companies 11
Ventilator Associated Pneumonia (VAP) - Therapeutics under Investigation by Universities/Institutes 13
Ventilator Associated Pneumonia (VAP) - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Ventilator Associated Pneumonia (VAP) - Products under Development by Companies 18
Ventilator Associated Pneumonia (VAP) - Products under Investigation by Universities/Institutes 19
Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development 20
Adenium Biotech ApS 20
AstraZeneca PLC 21
Cardeas Pharma Corp. 22
Cubist Pharmaceuticals, Inc. 23
Dong-A Socio Group 24
F. Hoffmann-La Roche Ltd. 25
KaloBios Pharmaceuticals, Inc. 26
Meiji Seika Pharma Co., Ltd. 27
Nabriva Therapeutics AG 28
Paratek Pharmaceuticals, Inc. 29
Savara Inc. 30
Serendex Pharmaceuticals A/S 31
Tetraphase Pharmaceuticals Inc. 32
Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Mechanism of Action 37
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
(amikacin + fosfomycin) - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(ceftazidime + avibactam) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(ceftolozane sulfate + tazobactam sodium) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
AA-139 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
arbekacin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BC-3781 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
eravacycline - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
fosfomycin - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
KB-001A - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MEDI-4893 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
molgramostim - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Nu-2 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
pseudomonas aeruginosa vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
pseudomonas and VAP conjugate vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Qn-2251 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
RG-7929 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecules for Infectious Diseases - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
tedizolid phosphate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
vancomycin hydrochloride - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Ventilator Associated Pneumonia (VAP) - Recent Pipeline Updates 73
Ventilator Associated Pneumonia (VAP) - Dormant Projects 93
Ventilator Associated Pneumonia (VAP) - Discontinued Products 94
Ventilator Associated Pneumonia (VAP) - Product Development Milestones 95
Featured News & Press Releases 95
May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 95
Appendix 96
Methodology 96
Coverage 96
Secondary Research 96
Primary Research 96
Expert Panel Validation 96
Contact Us 97
Disclaimer 97

List of Tables
Number of Products under Development for Ventilator Associated Pneumonia (VAP), H1 2015 9
Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Comparative Analysis by Unknown Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Investigation by Universities/Institutes, H1 2015 19
Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS, H1 2015 20
Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca PLC, H1 2015 21
Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp., H1 2015 22
Ventilator Associated Pneumonia (VAP) - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 23
Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Group, H1 2015 24
Ventilator Associated Pneumonia (VAP) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 25
Ventilator Associated Pneumonia (VAP) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 26
Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 27
Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics AG, H1 2015 28
Ventilator Associated Pneumonia (VAP) - Pipeline by Paratek Pharmaceuticals, Inc., H1 2015 29
Ventilator Associated Pneumonia (VAP) - Pipeline by Savara Inc., H1 2015 30
Ventilator Associated Pneumonia (VAP) - Pipeline by Serendex Pharmaceuticals A/S, H1 2015 31
Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 32
Assessment by Monotherapy Products, H1 2015 33
Assessment by Combination Products, H1 2015 34
Number of Products by Stage and Target, H1 2015 36
Number of Products by Stage and Mechanism of Action, H1 2015 38
Number of Products by Stage and Route of Administration, H1 2015 40
Number of Products by Stage and Molecule Type, H1 2015 42
Ventilator Associated Pneumonia (VAP) Therapeutics - Recent Pipeline Updates, H1 2015 73
Ventilator Associated Pneumonia (VAP) - Dormant Projects, H1 2015 93
Ventilator Associated Pneumonia (VAP) - Discontinued Products, H1 2015 94